Eli Lilly releases long-term research data on its treatment drug for Alzheimer's disease, the injection of solanezumab.

date
04/08/2025
On July 30th, Eli Lilly and Company announced the long-term extension results of its TRAILBLAZER-ALZ 2 Phase III clinical trial. The data showed that participants who received treatment with the injection of aducanumab experienced a significant slowing of disease progression compared to an untreated external cohort in the Alzheimer's Disease Neuroimaging Initiative (ADNI) database, and this benefit continued to increase over three years. Key preliminary results of the TRAILBLAZER-ALZ 2 LTE study include: 1. Participants who received treatment with the aducanumab injection showed sustained improvement in efficacy over three years compared to the ADNI reference group. The clinical dementia rating scale showed a slowing of cognitive decline by 0.6 points at 18 months and 1.2 points at 36 months. 2. Early use of the aducanumab injection reduced the risk of disease progression to the next stage by 27% compared to the delayed treatment group. 3. Over 75% of participants receiving the aducanumab injection achieved amyloid clearance within 76 weeks of treatment. 4. In participants who completed treatment, the longest observation period was 2.5 years, and the rate of amyloid plaque redeposition remained slow, consistent with previous studies and modeling results. 5. No new safety signals were observed during the three-year period of the LTE stage, further confirming the existing safety profile of the aducanumab injection. It is important to note that treatment targeting amyloid may result in imaging-related abnormalities, including edema/exudates and hemorrhage/iron deposition. These side effects are usually asymptomatic but can also lead to serious or even life-threatening symptoms. Patients carrying one or two copies of the Apolipoprotein E4 allele are at higher risk of developing Alzheimer's disease and experiencing ARIA. Patients should have thorough discussions with their doctors about safety concerns. Additionally, the aducanumab injection may cause certain types of allergic reactions, some of which may be severe and life-threatening, typically occurring during or within 30 minutes after infusion. Headache is another common side effect.